Increase the production of radioformatical production Own, it does not guarantee it to Europe, If the EU does not address its dependence According to raw materials from Russia and the United States and the European Union’s highest pharmaceutical officials, improve the performance of cross -war transport.
Given a continuous increase in demand for radioforms throughout Europe, The European Drugs Company (EMA) And bosses of pharmaceutical companies (HMA) issued a series of joint recommendations on Monday, in which the European Union insists on strengthening their distribution chain Focuses on complex vulnerabilities Beyond production.
Radioformes drugs They contain radioactive isotopes It is necessary to diagnose and treat diseases such as tumors. An example of the use of iodine Treatment of thyroid cancer to get images. Although they are safe for medical use, their radioactive nature Its production and its transportation Be particularly complicated and are very controlled.
Ema warns it The current EU delivery chain is not limited For low production capacity, but the fragment of the rules on transport, and the strong dependence of the third countries for the main raw materials. Last June, twenty -seven energy ministers called for guarantee to provide medical radioisotopes.
The pro -Russia and the United States of America
One of the main reasons for anxiety is the EU depends The most enriched uranium And a special fuel used in furnace that produces small concentrated (Halu), medical isotopes. In the present, Russia is the only supplier The business is capable of delivering large quantities of Halu through your state company Tenex.
AmericaAlthough this is not a more important supplier, Began to make Halu For the first time for more than 70 years in October 2023 nationally. In addition, French nuclear fuel fuel company Orano is reading the opportunity to develop uranium enrichment installation in the United States to reduce Russian imports.
To deal with these units, EMA recommends to develop enrichment skills Invest in Hallu and long -term solutions in the EU. The European Union has also supported initiatives such as the European Radiosotope Valley (ERVI) initiative, which is a part of the European Union plan for the Cancer (Strategic agenda for the medical use of ionizing radiation).
EU countries are promoted Mapting your entire delivery chain Radioformasuticals, from obtaining raw materials to final distribution, and examining national strategies that combine with a vast social structure. EMA recommendations are coming At the time when the EU reinstates the strategic value In medical radio isosotopes, its importance recognizes not only public health, but also for geopolitical setback and health sovereignty.
Bottle neck in transport and lead control
Although the increase in product is important, the EMA emphasizes that it is equal Disruptions in critic traffic. The company refers to the main obstacles to efficient distribution of protocol conflicts between member states and obsolete infrastructure. Radiofarmousatic This requires the consolidation of the most special containers, the strict deadline and the mosaic of the national regulations. All these factors will delay administration Key and emergency treatments.
In proposed solutions, EMA supports European standards Certificate of transport containers And mutual recognition of certificates between member states. Without this synchronization, the demand for demand continues to increase as delays and efficiency can be intensified. One of the challenges that comes with the ban on lead in transport containers. LeadUsually used to protect radioactive materials, It raises important risks For health and environment.
While the European Union has already banned lead particles in wetlands, widespread restrictions are being investigated, which will affect the radio distribution chain. However, EMA insists on the Commission to consider possible challenges And the consequences of this sector in the event of a leading ban.
